Adhere to the principle of benefiting the people, focus on reducing the burden of medical treatment on the masses, and seek medical treatment in different places
CCTV News: In recent years, the National Medical Insurance Administration has adhered to the principle of benefiting the people and focused on reducing the burden of medical treatment on the public. By accelerating the pace of medical insurance negotiations, it has promoted centralized and volume based procurement, while continuously overcoming bottlenecks and bottlenecks in remote medical treatment.
Last year, 275 negotiated drugs reduced the burden for patients by over 210 billion yuan
Since the establishment of the National Medical Insurance Administration in 2018, negotiations on the entry of medical insurance drug catalogs have been carried out for five consecutive years, with a total of 341 drugs added to the catalog through negotiations, with an average price reduction of over 50%. According to the announcement, in 2022, 275 negotiation drugs were reimbursed for 180 million people during the agreement period. By negotiating price reductions and medical insurance reimbursements, we have reduced the burden on patients by more than 210 billion yuan this year.
The total amount of orders for centralized procurement of drugs increased by 51.6 billion yuan compared to last year
In terms of centralized procurement of drugs and consumables, in 2022, the seventh batch of national organized centralized procurement of drugs involves 61 varieties, with an average price reduction of 48%. The national organization's collection of high-value medical consumables for orthopedics and spine included 5 types of orthopedic consumables, with an average decrease of 84%. According to the announcement, in 2022, the total amount of online procurement orders through provincial-level pharmaceutical centralized procurement platforms nationwide was 1085.6 billion yuan, an increase of 51.6 billion yuan from 2021. Including 881 billion yuan for western medicine and 204.6 billion yuan for traditional Chinese patent medicines and simple preparations, an increase of 49.5 billion yuan and 2.1 billion yuan respectively over 2021. The public has used more high-quality and affordable medicines and consumables.
Further expanding the scope of direct settlement for medical treatment across provinces and regions
In order to facilitate people's medical treatment in different regions, in recent years, the scope of cross provincial direct settlement for medical treatment has been further expanded, achieving that at least one designated medical institution in each county can provide cross provincial direct settlement services for medical expenses, including outpatient expenses.
According to the announcement, in 2022, the number of designated medical institutions with hospital and outpatient expenses connected across provinces reached 62700 and 88700 respectively, and the number of designated retail pharmacies connected across provinces reached 226200. The hospitalization expenses were directly settled across provinces for 5.6879 million people, reducing the advance payment of 76.233 billion yuan for insured individuals; Outpatient expenses were directly settled across provinces for 32.4356 million people, reducing advance payments of 4.685 billion yuan for insured individuals.